Latigo Biotherapeutics, Inc.
LTGO evidence brief
What we can confirm
- BioSniper Score:
- 5.0 / 10
- Market Cap:
- $1.57B
What it means
What to watch
Prepared research question
What matters most for LTGO—catalysts, financial risk and supporting evidence?
Traceable citations · Unknowns marked
BioSniper AI · LTGO
Latigo Biotherapeutics, Inc. (LTGO) is a publicly traded biotechnology company focused on developing onzotrigine (LTG-001) for acute pain, having completed an upsized IPO raising $397.4 million in gross proceeds to fund operations into 2029.
Key risk: Negative shareholders' equity
BioSniper Score
Based on 2 of 6 signals
Limited data coverage
Market Cap
$1.57B
Cash Runway
—
Lead Asset
—
Next Catalyst
—
Financial data as of Jun 30, 2026.
Tracking 5 clinical trials for Latigo Biotherapeutics, Inc..
Latigo Biotherapeutics, Inc. (LTGO) is a publicly traded biotechnology company focused on developing onzotrigine (LTG-001) for acute pain, having completed an upsized IPO raising $397.4 million in gross proceeds to fund operations into 2029.
- Completed an upsized initial public offering, including full exercise of the underwriters’ option to purchase additional shares, raising gross proceeds of $397.4 million [news · 2026-09-03].
- Cash and equivalents of $55.0M as of 2026-06-30 [sec].
- Net income of -$25.8M as of 2026-06-30 [sec].
- Shareholders' equity of -$276.1M as of 2026-06-30 [sec].
- Total debt of $35.0M as of 2026-06-30 [sec].
What works
- Completed a $397.4 million upsized IPO, with existing cash expected to fund operations into 2029 [news · 2026-09-03].
- Positive onzotrigine (LTG-001) abdominoplasty clinical trial results published in The New England Journal of Medicine [news · 2026-09-03].
- Expanded leadership team with appointment of Naomi Lowy, M.D., former deputy director [news · 2026-09-03].
What to weigh
- Net loss of -$25.8M as of 2026-06-30 [sec].
- Negative shareholders' equity of -$276.1M as of 2026-06-30 [sec].
- Total debt of $35.0M as of 2026-06-30 [sec].
From the filings
Quoted directly from source documents.
IPO raised $397.4 million in gross proceeds
“Completed upsized initial public offering, including full exercise of the underwriters’ option to purchase additional shares, raising gross proceeds of $397.4 million”
News · September 3, 2026
Positive onzotrigine abdominoplasty trial results published
“The New England Journal of Medicine published positive onzotrigine (previously referred to as LTG-001) abdominoplasty clinical trial results in moderate-to-severe acute pain”
News · September 3, 2026
Catalyst timeline
- 2023-10-17 · Phase 1 start for LTG-001 (oral and IV administration) — Initiated a sequential, randomized, double-blind, placebo-controlled Phase 1 study to evaluate safety, tolerability, and pharmacokinetics.
- 2024-12-19 · Phase 2 start for LTG-001 in acute pain after third molar surgery — Began a Phase 2, randomized, double-blind, placebo-controlled, dose-ranging study for acute pain after surgical removal of impacted third molars.
- 2025-07-24 · Phase 2 start for LTG-001 in acute pain after abdominoplasty — Began a Phase 2, randomized, double-blind, placebo-controlled, dose-ranging study for acute pain after abdominoplasty.
- 2025-09-03 · Phase 1 start for another program (LTG-001 or related) — Initiated a Phase 1 study, though the specific compound and indication are not fully detailed in the available data.
Risks & what to watch (4)›
Key risks
- Negative shareholders' equity — Shareholders' equity of -$276.1M as of 2026-06-30 indicates liabilities exceed assets [sec].
- Ongoing net losses — Net loss of -$25.8M as of 2026-06-30 shows continued operating losses [sec].
- Debt burden — Total debt of $35.0M as of 2026-06-30 adds financial obligation [sec].
- Clinical-stage revenue risk — No approved products; revenue depends on successful clinical development and regulatory approval [news].
What to watch
- Progress of onzotrigine (LTG-001) through Phase 2 trials for acute pain, including the abdominoplasty and third molar extraction studies [catalyst].
- Cash runway and burn rate given $55.0M cash and expected funding into 2029 [news · 2026-09-03].
- Any future clinical data readouts or regulatory milestones for LTG-001 [news].
Sources: Catalysts · Competitor trials · News · Generated October 5, 2026 · How we verify sources →
Run Latigo Biotherapeutics, Inc. through your own thesis
Use the pipeline, catalyst, financial, FDA, and market facts on this page as inputs to a protocol you control.
Your protocol can:
- Turn available Latigo Biotherapeutics, Inc. facts into screen rules or deeper checks
- Show cited findings, blockers, and unresolved evidence together
- Save the logic and rerun it as the company evidence changes
Evidence & data
Score breakdownBased on 2 of 6 signals · derived from public data
Pipeline inputs are unavailable for this score. It uses only the available signals shown below.
Cash runway data unavailable
Net income -$26M
No tracked pipeline phase
No tracked pipeline candidates
No upcoming catalysts tracked
2 buys · 0 sells (180d)
Regulatory
Financials
Frequently asked questions
What is the AI investment thesis for Latigo Biotherapeutics, Inc.?
Latigo Biotherapeutics, Inc. (LTGO) is a publicly traded biotechnology company focused on developing onzotrigine (LTG-001) for acute pain, having completed an upsized IPO raising $397.4 million in gross proceeds to fund operations into 2029.
Who is the CEO of Latigo Biotherapeutics, Inc.?
Mr. Nima Farzan M.B.A. is the chief executive officer of Latigo Biotherapeutics, Inc. (LTGO).
Where is Latigo Biotherapeutics, Inc. headquartered?
Latigo Biotherapeutics, Inc. (LTGO) is headquartered in Thousand Oaks, CA, United States.
What therapeutic areas does Latigo Biotherapeutics, Inc. focus on?
Latigo Biotherapeutics, Inc. develops therapies across Oncology, Pain.
The AI overview and BioSniper Score are neutral, data-derived signals built from public SEC filings, ClinicalTrials.gov and FDA records — not investment advice.